Earlier this week, Bristol-Myers Squibb an­nounced that it had filed an appli­ca­tion to have elotuzumab approved in Europe as a new treat­ment for mul­ti­ple mye­lo­ma patients who have re­ceived one or more prior ther­a­pies (see re­lated Bristol-Myers press re­lease).

An im­por­tant part of elotuzumab’s Euro­pean ap­prov­al appli­ca­tion will be ef­fi­cacy and safety data from a Phase 3 clin­i­cal trial known as ELOQUENT-2. These re­sults drew sig­nif­i­cant attention when they were pre­sented at this summer’s Amer­i­can Society of Clinical Oncology (ASCO) and Euro­pean Hema­tology Associ­a­tion …